

In the claims:

1-94. (Canceled)

95. (Currently Amended) A therapeutic composition, comprising a first isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:6, ~~SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:16;~~

(b) a polypeptide comprising at least a portion part of the a-sequence as described in (a) above and has an epitope in common therewith, wherein the portion is selected from the group consisting of the following peptides, or an epitope-containing portion thereof:

Fel 16 (residues 20-41 of SEQ ID NO:6),

Fel 17 (residues 31-52 of SEQ ID NO:6)

Fel 32-1 (residues 31-43 of SEQ ID NO:6),

Fel 32-2 (residues 33-43 of SEQ ID NO:6),

Fel 32-3 (residues 35-43 of SEQ ID NO:6),

Fel 18 (residues 42-67 of SEQ ID NO:6),

Fel 33-1 (residues 45-55 of SEQ ID NO:6),

Fel 33-2 (residues 45-57 of SEQ ID NO:6),

Fel 33-3 (residues 45-59 of SEQ ID NO:6),

Fel 31-1 (residues 33-59 of SEQ ID NO:6),

Fel 31-2 (residues 33-58 of SEQ ID NO:6),

Fel 31-3 (residues 33-57 of SEQ ID NO:6),

Fel 31-4 (residues 33-56 of SEQ ID NO:6),

Fel 31-5 (residues 33-55 of SE ID NO:6),

Fel 31-6 (residues 34-59 of SEQ ID NO:6),

Fel 31-7 (residues 34-55 of SEQ ID NO:6),

Fel 20-1 (residues 53-78 of SEQ ID NO:6),

Fel 25 (residues 68-87 of SEQ ID NO:6),

Fel 28 (residues 79-101 of SEQ ID NO:6); and

(c) a modified form of a polypeptide as described in (a) or (b) above, which has at least one epitope in common therewith;

wherein said composition can be used to reduce an allergic response to a cat antigen in an individual sensitive to said antigen.

96. (Original) A composition according to claim 95 comprising a mixture of said first polypeptides.

97-100. (Canceled)

101. (Currently Amended) An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:6, ~~SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:16;~~

(b) a polypeptide comprising at least a portion part of the a-sequence as described in (a) above and has an epitope in common therewith, wherein the portion is selected from the group consisting of the following peptides, or an epitope-containing portion thereof:

Fel 16 (residues 20-41 of SEQ ID NO:6),

Fel 17 (residues 31-52 of SEQ ID NO:6)

Fel 32-1 (residues 31-43 of SEQ ID NO:6),

Fel 32-2 (residues 33-43 of SEQ ID NO:6),

Fel 32-3 (residues 35-43 of SEQ ID NO:6),

Fel 18 (residues 42-67 of SEQ ID NO:6),

Fel 33-1 (residues 45-55 of SEQ ID NO:6),

Fel 33-2 (residues 45-57 of SEQ ID NO:6),

Fel 33-3 (residues 45-59 of SEQ ID NO:6),

Fel 31-1 (residues 33-59 of SEQ ID NO:6),

Fel 31-2 (residues 33-58 of SEQ ID NO:6),

Fel 31-3 (residues 33-57 of SEQ ID NO:6),

Fel 31-4 (residues 33-56 of SEQ ID NO:6),

Fel 31-5 (residues 33-55 of SE ID NO:6),

Fel 31-6 (residues 34-59 of SEQ ID NO:6),

Fel 31-7 (residues 34-55 of SEQ ID NO:6),

Fel 20-1 (residues 53-78 of SEQ ID NO:6),

Fel 25 (residues 68-87 of SEQ ID NO:6),

Fel 28 (residues 79-101 of SEQ ID NO:6); and

(c) a modified form of a polypeptide as described in (a) or (b) above, which has at least one epitope in common therewith.

102. (Currently Amended) A polypeptide according claim 101, wherein the polypeptide has a stimulation index of at least ~~approximately~~ 4.0 or a positivity index of at least ~~approximately~~ 250, wherein the stimulation index is defined as the ratio of measured proliferation of T cells and antigen presenting cells from a responding individual when exposed to antigen, to the measured proliferation of said cells in the absence of antigen, and wherein the positivity index is defined as the average stimulation index of a population of responding individuals tested multiplied by the percentage of individuals in the population exhibiting a positive response.

103. (Original) A polypeptide according to claim 101, produced recombinantly.

104. (Original) A polypeptide according to claim 101, produced by chemical synthesis.

105-110. (Canceled)